INVA vs SGRY

Innoviva exhibits a stark divergence between operational health trends and valuation; while the Piotroski F-Score of 3/9 indicates weak financial health trends, the company is fundamentally undervalued with a current price of $23.76 sitting well below both the Graham Number ($34.16) and the Intrinsic Value ($97.35). The company boasts exceptional profitability with a 65.92% profit margin and a PEG ratio of 0.35, suggesting massive growth potential relative to its current multiple. Despite a heavily bearish technical trend (10/100), the extreme liquidity (Current Ratio 14.64) and low debt/equity (0.28) mitigate immediate solvency risks. The bullish thesis is driven by deep value and explosive earnings growth, though the low F-Score warrants caution regarding operational efficiency.

SGRY exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the stock trades at a low Price-to-Sales (0.55) and Price-to-Book (1.05) ratio, these valuation metrics are offset by negative profit margins and a disastrous earnings track record, with 0 beats in the last four quarters. Stagnant revenue growth (2.40%) and aggressive insider selling by the CEO and CFO further undermine the bullish analyst consensus. The combination of a 0/100 technical trend and consistent earnings misses suggests a value trap rather than a value opportunity.